A Phase 1, Dose Escalation Study of the Safety and Pharmacokinetics of ALB 109564(a) Administered Intravenously Every 3 Weeks to Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1, Dose Escalation Study of the Safety and Pharmacokinetics of ALB 109564(a) Administered Intravenously Every 3 Weeks to Subjects With Advanced Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2014

At a glance

  • Drugs ALB 109564A (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors AMRI
  • Most Recent Events

    • 26 Aug 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 09 Mar 2011 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 01 Jun 2010 Promising interim results have been reported in a media release from AMRI (Albany Molecular Research, Inc.) and will be presented at ASCO 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top